Bosch / Noort Schizophrenia, Sleep, and Acupuncture

1. Auflage 2009
ISBN: 978-1-61676-355-8
Verlag: Hogrefe Publishing
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 360 Seiten

This book is an introduction for professionals in Western medicine and for acupuncturists on the use of acupuncture in treatment of schizophrenia and sleep disorders.

Acupuncture has long been used in Traditional Chinese Medicine (TCM) in mental health and sleep disorders. This book aims to build a bridge between “conventional” medicine research and practice, which is increasingly interested in the benefits of acupuncture but often not aware of the considerable knowledge and experience available, and TCM/acupuncture where understanding of conventional Western concepts of and approaches to schizophrenia may be lacking. Acupuncture has, for instance, been shown to normalize levels of neurotransmitters involved in sleep and schizophrenia.

Contributions by leading experts from both the Western and Chinese traditions deal with: current concepts of schizophrenia, pharmacotherapy, practical experience, cross-cultural differences, comparisons of TCM/Western diagnoses, sleep disturbances, effects of acupuncture on neurotransmitters, philosophy of TCM, neuroimaging studies, recent research results from East and West on TCM and acupuncture treatments for schizophrenia.

Autoren/Hrsg.

Bosch, Peggy

Noort, Moritz W. van den

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Komplementäre Medizin, Asiatische Medizin (TCM), Heilpraktiker Akupunktur
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Schlafmedizin & Schlafforschung
• Sozialwissenschaften Psychologie Psychotherapie / Klinische Psychologie Psychopathologie

Inhaltsverzeichnis

1;Table of Contents;6
2;Preface;8
3;1 An Introduction to Schizophrenia;14
4;2 Schizophrenia: What Do We Know from Neuroimaging Research?;29
5;3 The Pharmacotherapy of Schizophrenia: Past, Present, and Possible Future;48
6;4 Treatment of Patients with Schizophrenia in Practice: Emphasizing Early Warning Symptoms;71
7;5 A Cross-Cultural Approach to the Diagnosis and Management of Schizophrenia;81
8;6 What is Sleep and What Can Go Wrong with Sleep?;98
9;7 Sleep of Patients with Schizophrenia On and Off Melatonin Treatment: Contradictions and Hypothesis;117
10;8 An Introduction to Traditional Chinese Medicine;135
11;9 The Philosophy Behind Traditional Chinese Medicine;159
12;10 Acupuncture Modalities, Methodology, and Key Problems for Western Scientific Research;175
13;11 The Search for the Mechanism Behind Acupuncture: Research with Neuroimaging;188
14;12 Acupuncture and the Dopaminergic System;215
15;13 Acupuncture and Sleep: Can Acupuncture Be Used in the Treatment of Insomnia and Schizophrenia?;262
16;14 Traditional Chinese Medicine and Psychological Disorders;280
17;15 Acupuncture and Moxibustion as Treatments for Schizophrenia and Sleep Disturbances;298
18;16 Acupuncture in the Treatment of Schizophrenia: A Case Study;319
19;Conclusions;340
20;Contributors;342
21;Index;348

Leseproben

Epidemiology (p. 6)

It is a common belief that schizophrenia is fairly evenly distributed around the globe and affects females and males equally. There are quite large variations in both point prevalences and annual incidences, however. Based on extensive reviews of available studies, McGrath and collaborators (McGrath, 2005, 2006) found that the median incidence was 15.2 per 100,000, with a range between the 10th and the 90th percentile of 7.7 to 43.0 per 100,000, which is a five-fold variation. Males were found to develop schizophrenia more often than females (median male to female risk ratio = 1.4). Based on studies from 1965 to 2002 (Saha, Chant, Welham, &, McGath, 2005) median point prevalence was 4.6/1000 with a range between the 10th and 90th percentile of 1.9 to 10 per 1,000, a five-fold variation. Some of the variance may be explained by variation in methodology, but chances are that the rates of schizophrenia differ across time, space, and sexes. There is compelling evidence that the risk of schizophrenia is a result of a genotype- by-environment interaction and there are reasons to believe that the distribution of genes and environmental risk factors differ across human populations and time periods.

The mean lifetime risk for schizophrenia is close to 1% in aWestern European population. If both parents or a monozygotic twin have the diagnosis the risk is close to 50%, falling to approximately 10% if the diseased relative is a dizygotic twin/sibling. Interestingly, some studies have shown that older age of the father will increase the risk of schizophrenia for the offspring (Sipos et al., 2004). Epidemiologic studies, including family, twin, and adoption studies, provide evidence both for a high degree of genetic heritability and for the importance of the environment. The search for genes implicated in schizophrenia has been difficult and despite an estimated total heritability of approximately 80% it has been hard to find susceptibility genes with more than small effects. At the same time, more powerful environmental factors have been identified (Cannon &, Clarke, 2005).

In Table 2 several environmental factors found to increase the risk of schizophrenia above the population risk are listed. The prenatal period seems to be especially vulnerable around the second trimester. In this period, prenatal risk factors may double the risk for the offspring.Obstetric complications also double the risk. Winter birth has a much smaller effect (5–8% increase). In the context of risk factors for schizophrenia, cannabis has become a drug of increasing importance (Di Forti, Morrison, Butt, &, Murray, 2007). It is consumed by approximately 4% of the adult population. Particularly, European countries have seen a rise in consumption of high potency preparations in a still younger population. The CB1 receptors in the brain are normally activated by the endocannabinoids. The active ingredient of cannabis, [DELTA]9 – tetrahydrocannabinol appears to disrupt normal CB1 mediated signaling, increases dopaminergic neuronal firing, and many heavy users will develop problems.